An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

• Status: Completed
• Trial end date: 2019-10-29
• Target enrollment: 0
• Participant gender: Male

Summary

Study of what the body does to drug BMS-986165 when it is taken together with pyrimethamine

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BMS-986165; Pyrimethamine

Criteria

Inclusion Criteria:

• Patients must be willing and able to complete all study-specific procedures and visits

• Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations

• Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening

• Normal renal function at screening

Exclusion Criteria:

• Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease

• Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug

• History or presence of clinically significant acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening

• Additional criteria may apply